CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Crixotinib 200 mg and Sunitinib Cohort 1|DRUG: Crixotinib 250 mg and Sunitinib Cohort 2|DRUG: Crizotinib & Sunitinib 37.5 mg Cohort 3
Sponsor: Mothaffar Rimawi